BioSpace20h
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
Le Lézard19h
AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
AstronauTx Ltd ('AstronauTx'), a biotechnology company developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, Ph.
Le Lézard1h
Volastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in Ovarian Cancer
Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company's internally ...
'It raises hope': A new drug for schizophrenia approved for the first time in 70 years
The Food and Drug Administration in the US has just approved Cobenfy, which one researcher referred to as a "game changer" ...
Sydney Morning Herald17h
The Australian research (and brains) that led to a new schizophrenia drug
US researchers at pharmaceutical company Eli Lilly were investigating the drug xanomeline – which activates muscarinic ...
The New York Times15h
New York Times - Top Stories
The attack, which ended shortly after it began, capped a chaotic 24-hour period that began with Israel’s invading of Lebanon in pursuit of Hezbollah. Iran fired a barrage of ballistic missiles ...